|
JPH0637520B2
(ja)
*
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
|
US4973577A
(en)
*
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
WO1992004913A1
(en)
|
1990-09-13 |
1992-04-02 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
|
US5118667A
(en)
*
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
|
US5885794A
(en)
*
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
|
US6162896A
(en)
*
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
|
AU654724B2
(en)
|
1991-05-10 |
1994-11-17 |
Salk Institute For Biological Studies, The |
Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
|
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
|
DK0592562T3
(da)
|
1991-06-25 |
1999-08-30 |
Genetics Inst |
BMP-9-præparater
|
|
US6692925B1
(en)
*
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
WO1994015965A1
(en)
|
1993-01-12 |
1994-07-21 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
|
AU677849B2
(en)
|
1993-05-12 |
1997-05-08 |
Genetics Institute, Llc |
BMP-10 compositions
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5831050A
(en)
*
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
|
JPH09503673A
(ja)
|
1993-10-14 |
1997-04-15 |
プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ |
ニューロン細胞の誘導および維持法
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5658876A
(en)
*
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
|
DK0776337T3
(da)
*
|
1994-07-08 |
2005-12-12 |
Univ Johns Hopkins Med |
Vækstdifferentieringsfaktor-11
|
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
ATE352638T1
(de)
|
1995-04-11 |
2007-02-15 |
Gen Hospital Corp |
REVERSE ßTWO-HYBRIDß-SYSTEME
|
|
US6132988A
(en)
*
|
1995-10-27 |
2000-10-17 |
Takeda Chemical Industries, Ltd. |
DNA encoding a neuronal cell-specific receptor protein
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US20050244867A1
(en)
*
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
US6004780A
(en)
*
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
JP2001503266A
(ja)
|
1996-10-25 |
2001-03-13 |
ジー．ディー．サール アンド カンパニー |
環状に並べ替えたエリスロポイエチン受容体アゴニスト
|
|
US6605699B1
(en)
*
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
|
US7041641B2
(en)
*
|
1997-03-20 |
2006-05-09 |
Stryker Corporation |
Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
|
|
US6426411B1
(en)
*
|
1997-05-30 |
2002-07-30 |
Dana-Farber Cancer Institute |
PGC-1, a novel brown fat pparγ coactivator
|
|
US6231880B1
(en)
*
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
|
US6696260B1
(en)
*
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
|
AU8666398A
(en)
|
1997-08-01 |
1999-02-22 |
Johns Hopkins University School Of Medicine, The |
Methods to identify growth differentiation factor (gdf) receptors
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
US6656475B1
(en)
*
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
|
US6953662B2
(en)
*
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
|
AU8921698A
(en)
|
1997-08-29 |
1999-03-16 |
Human Genome Sciences, Inc. |
Follistatin-3
|
|
US6696411B1
(en)
*
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
|
JP2002524514A
(ja)
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
DE69934995T2
(de)
*
|
1998-09-22 |
2007-11-22 |
Long Yu |
Für den menschlichen wachstums-differenzierungsfaktor kodierende sequenz und polypeptid, welches durch solche dna-sequenz kodiert wird und verfahren zur herstellung
|
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
|
US6238860B1
(en)
|
1998-11-05 |
2001-05-29 |
Dyax Corp. |
Binding moieties for human parvovirus B19
|
|
US6777205B1
(en)
*
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
EP1147413B1
(en)
|
1999-01-21 |
2006-04-05 |
Metamorphix, Inc. |
Growth differentiation factor inhibitors and uses therefor
|
|
CA2365449A1
(en)
|
1999-04-19 |
2000-10-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibitor of the growth of androgen-independent tumor
|
|
US6468543B1
(en)
*
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
|
IL149267A0
(en)
|
1999-11-12 |
2002-11-10 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
|
DE60026592T2
(de)
|
1999-12-15 |
2006-12-14 |
Research Development Foundation, Carson City |
Betaglycan als ein inhibin rezeptor und dessen verwendung
|
|
JP4487376B2
(ja)
*
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
|
ATE291436T2
(de)
|
2000-05-15 |
2005-04-15 |
Hoffmann La Roche |
Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
|
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
|
EP1303605A2
(en)
|
2000-07-19 |
2003-04-23 |
Eli Lilly And Company |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
|
DK1345959T3
(da)
|
2000-11-20 |
2011-09-05 |
Univ Illinois |
Membranscaffoldproteiner
|
|
AU2002236558A1
(en)
|
2000-12-01 |
2002-06-11 |
Regents Of The University Of California |
Method and composition for modulating bone growth
|
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
|
US20040132675A1
(en)
*
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
|
US7294472B2
(en)
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
|
WO2002074340A1
(fr)
|
2001-03-16 |
2002-09-26 |
Takeda Chemical Industries, Ltd. |
Procede de fabrication d'une preparation a liberation continue
|
|
KR100976743B1
(ko)
|
2001-05-24 |
2010-08-19 |
지모제넥틱스, 인코포레이티드 |
Ｔａｃｉ-면역글로불린 융합 단백질
|
|
US7074901B2
(en)
|
2001-05-25 |
2006-07-11 |
Serono Genetics Institute S.A. |
Isolated human vCOL16A1 polypeptide and fragments thereof
|
|
AUPR638101A0
(en)
*
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
|
US6855344B2
(en)
*
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
|
CN100419425C
(zh)
*
|
2001-07-17 |
2008-09-17 |
帝人株式会社 |
通过测定PPARδ激活作用筛选物质的方法和药剂
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
US7320789B2
(en)
*
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US6784154B2
(en)
*
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
|
CN102526044A
(zh)
|
2001-12-06 |
2012-07-04 |
法布罗根股份有限公司 |
提高内源性红细胞生成素(epo)的方法
|
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
|
WO2003068801A2
(en)
|
2002-02-11 |
2003-08-21 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
PL375045A1
(en)
*
|
2002-02-21 |
2005-11-14 |
Wyeth |
Gasp1: a follistatin domain containing protein
|
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
|
WO2003087162A2
(en)
|
2002-04-18 |
2003-10-23 |
Mtm Laboratories Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
|
US7632679B2
(en)
*
|
2002-07-16 |
2009-12-15 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for screening for modulators of neural differentiation
|
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
|
BR0313729A
(pt)
|
2002-08-16 |
2005-06-21 |
Wyeth Corp |
Elemento respondente a estrogênio bmp-2 e métodos de uso do mesmo
|
|
US7842691B2
(en)
|
2002-10-15 |
2010-11-30 |
Celgene Corporation |
Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
|
|
AR047392A1
(es)
*
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
|
US20040223966A1
(en)
*
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
|
US9682054B2
(en)
|
2003-02-07 |
2017-06-20 |
Prometic Pharma Smt Limited |
Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
|
|
US20070155661A1
(en)
|
2003-02-14 |
2007-07-05 |
The Board Of Trustees Of The Leland Standord Junior University |
Methods and compositions for modulating the development of stem cells
|
|
GB0304424D0
(en)
|
2003-02-26 |
2003-04-02 |
Glaxosmithkline Biolog Sa |
Novel compounds
|
|
WO2004086953A2
(en)
|
2003-03-26 |
2004-10-14 |
The Board Of Trustees Of The University Of Arkansas |
Method for diagnosis and treatment of bone turnover
|
|
WO2005028517A2
(en)
|
2003-05-09 |
2005-03-31 |
The General Hospital Corporation |
SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
|
|
WO2004108157A2
(en)
|
2003-06-02 |
2004-12-16 |
Wyeth |
Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
|
|
EP1636270B1
(en)
|
2003-06-16 |
2016-07-20 |
UCB Pharma S.A. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
|
WO2005025601A1
(en)
|
2003-09-15 |
2005-03-24 |
Monash University |
Follistatin isoforms and uses thereof
|
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
|
ATE443724T1
(de)
|
2004-01-22 |
2009-10-15 |
Merck Patent Gmbh |
Antikrebs-antikörper mit reduzierter komplementfixierung
|
|
US20050197292A1
(en)
*
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
|
EP1732589A2
(en)
|
2004-03-26 |
2006-12-20 |
Acceleron Pharma Inc. |
Bmp-3 propeptides and related methods
|
|
JP2008500816A
(ja)
|
2004-03-31 |
2008-01-17 |
ゼンコー・インコーポレイテッド |
改善された性質を有するｂｍｐ−７変異体
|
|
JP4688483B2
(ja)
|
2004-04-15 |
2011-05-25 |
株式会社テクノネットワーク四国 |
フォリスタチン変異体ポリペプチド
|
|
US7741284B2
(en)
|
2004-05-12 |
2010-06-22 |
Acceleron Pharma Inc. |
BMP10 propeptides and related methods
|
|
US20100183695A1
(en)
|
2004-05-27 |
2010-07-22 |
John Knopf |
Cerberus/coco derivatives and uses thereof
|
|
AU2005258286A1
(en)
|
2004-06-24 |
2006-01-05 |
Acceleron Pharma Inc. |
GDF3 propeptides and related methods
|
|
ES2561048T3
(es)
*
|
2004-07-23 |
2016-02-24 |
Acceleron Pharma Inc. |
Polipéptidos del receptor ActRII
|
|
US8288557B2
(en)
|
2004-07-23 |
2012-10-16 |
Endocyte, Inc. |
Bivalent linkers and conjugates thereof
|
|
US20060034831A1
(en)
|
2004-08-12 |
2006-02-16 |
Wyeth |
Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
|
|
CA2581896C
(en)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
|
US20090144836A1
(en)
*
|
2004-11-24 |
2009-06-04 |
Koninklijke Philips Electronics, N.V. |
Decoding/decrypting based on security score
|
|
US20070003576A1
(en)
|
2004-12-09 |
2007-01-04 |
Andrea Gambotto |
Vaccines for the rapid response to pandemic avian influenza
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
EP1858541B1
(en)
|
2005-02-16 |
2012-07-25 |
The General Hospital Corporation |
Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency
|
|
EP1884235A1
(en)
|
2005-04-26 |
2008-02-06 |
Ajinomoto Co., Inc. |
Myeloerythroid progenitor differentiation inducer
|
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
|
US20070238658A1
(en)
|
2005-09-28 |
2007-10-11 |
Levin Steven D |
IL-17A and IL-17F Antagonists and Methods of Using the Same
|
|
JP5361386B2
(ja)
|
2005-10-07 |
2013-12-04 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ |
マトリックスメタロプロテイナーゼ１１ワクチン
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
ME00380B
(me)
|
2005-11-23 |
2011-10-10 |
Acceleron Pharma Inc |
Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
|
|
CA2632544C
(en)
|
2005-12-06 |
2014-09-23 |
Amgen Inc. |
Use of myostatin antagonist for treating the effects of hypogonadism
|
|
WO2007071023A1
(en)
|
2005-12-20 |
2007-06-28 |
Merck Frosst Canada Ltd. |
Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
|
US20070161578A1
(en)
|
2005-12-21 |
2007-07-12 |
Hwa Joyce J |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
|
|
EP1973909A2
(en)
|
2005-12-22 |
2008-10-01 |
Biogen Idec MA Inc. |
Transforming growth factor modulators
|
|
WO2007084976A2
(en)
*
|
2006-01-20 |
2007-07-26 |
Beckman Coulter, Inc. |
Methods of detection of iron deficiency
|
|
WO2007087505A2
(en)
|
2006-01-25 |
2007-08-02 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
|
MX2008011022A
(es)
|
2006-02-28 |
2008-09-10 |
Wellstat Therapeutics Corp |
Compuestos para el tratamiento de trastornos metabolicos.
|
|
WO2007109686A2
(en)
|
2006-03-20 |
2007-09-27 |
University Of Pittsburgh |
Immunomodulation of inflammatory conditions utilizing follistatin-like protein-1 and agents that bind thereto
|
|
WO2007120767A2
(en)
*
|
2006-04-14 |
2007-10-25 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
|
WO2007133653A2
(en)
*
|
2006-05-09 |
2007-11-22 |
Hemaquest Pharmaceuticals, Inc. |
Methods for treating blood disorders
|
|
EP2484352B1
(en)
*
|
2006-07-21 |
2014-07-09 |
Lyne Laboratories, Inc. |
Liquid compositions of calcium acetate
|
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US7547781B2
(en)
*
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
|
ES2569365T3
(es)
|
2006-11-29 |
2016-05-10 |
Nationwide Children's Hospital |
Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
|
|
US20100003190A1
(en)
|
2006-12-08 |
2010-01-07 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
|
|
CA2672581A1
(en)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
|
|
CN104524548A
(zh)
*
|
2006-12-18 |
2015-04-22 |
阿塞勒隆制药公司 |
活化素-actrii拮抗剂及在提高红细胞水平中的用途
|
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
US9526759B2
(en)
*
|
2007-02-01 |
2016-12-27 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for treating or preventing breast cancer
|
|
TW201940502A
(zh)
*
|
2007-02-02 |
2019-10-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
KR101672156B1
(ko)
*
|
2007-02-09 |
2016-11-02 |
악셀레론 파마 인코포레이티드 |
액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
|
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
US8236751B2
(en)
|
2007-03-07 |
2012-08-07 |
The Johns Hopkins University |
Methods of increasing muscle mass using follistatin-like related gene (FLRG)
|
|
CA2685306A1
(en)
|
2007-06-01 |
2008-12-11 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
PE20090510A1
(es)
|
2007-08-03 |
2009-05-22 |
Summit Corp Plc |
Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
|
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
|
CN107412734A
(zh)
|
2007-09-18 |
2017-12-01 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
AU2008330125B2
(en)
|
2007-11-21 |
2012-11-22 |
Amgen Inc. |
Wise binding antibodies and epitopes
|
|
WO2009137075A1
(en)
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
|
JP2011523357A
(ja)
|
2008-05-06 |
2011-08-11 |
ジョスリン ダイアビーティス センター インコーポレイテッド |
褐色脂肪細胞分化を誘導するための方法および組成物
|
|
CN107252486B
(zh)
|
2008-06-26 |
2021-10-22 |
阿塞勒隆制药公司 |
激活素-actrii的拮抗剂及在提高红细胞水平中的用途
|
|
KR101871510B1
(ko)
|
2008-06-26 |
2018-06-26 |
악셀레론 파마 인코포레이티드 |
액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
|
|
LT3750552T
(lt)
|
2008-08-14 |
2023-06-26 |
Acceleron Pharma Inc. |
Gdf gaudyklės
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
CA2749544A1
(en)
|
2009-01-13 |
2010-07-22 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
EA027071B1
(ru)
*
|
2009-04-27 |
2017-06-30 |
Новартис Аг |
АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
|
|
MX385318B
(es)
|
2009-06-08 |
2025-03-18 |
Acceleron Pharma Inc |
Metodos para aumentar adipocitos termogenicos.
|
|
JP2012529294A
(ja)
|
2009-06-12 |
2012-11-22 |
アクセルロン ファーマ， インコーポレイテッド |
切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
|
|
CA2770822C
(en)
|
2009-08-13 |
2020-03-24 |
Acceleron Pharma Inc. |
Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
|
|
ES2613523T3
(es)
|
2009-09-09 |
2017-05-24 |
Acceleron Pharma, Inc. |
Antagonistas de ActRIIb y dosificación y usos de los mismos
|
|
US20110129469A1
(en)
|
2009-11-03 |
2011-06-02 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
EP2501400B1
(en)
|
2009-11-17 |
2017-11-01 |
Acceleron Pharma, Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
|
US9595813B2
(en)
|
2011-01-24 |
2017-03-14 |
Soraa Laser Diode, Inc. |
Laser package having multiple emitters configured on a substrate member
|
|
JP6472999B2
(ja)
|
2011-07-01 |
2019-02-20 |
ノバルティス アーゲー |
代謝障害を治療するための方法
|
|
EP3520805B1
(en)
|
2011-10-17 |
2021-03-10 |
Acceleron Pharma Inc. |
Compositions for treating myelofibrosis
|
|
WO2013063536A1
(en)
|
2011-10-27 |
2013-05-02 |
Acceleron Pharma, Inc. |
Actriib binding agents and uses thereof
|
|
CN104411720B
(zh)
|
2012-07-02 |
2018-05-11 |
协和发酵麒麟株式会社 |
以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
|
|
JP6401172B2
(ja)
|
2012-10-24 |
2018-10-10 |
セルジーン コーポレイション |
貧血の治療方法
|
|
MX388380B
(es)
|
2014-04-18 |
2025-03-19 |
Acceleron Pharma Inc |
Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
|
|
KR20170035891A
(ko)
|
2014-06-13 |
2017-03-31 |
산타 마리아 바이오테라퓨틱스, 인코포레이티드 |
제형화된 수용체 폴리펩타이드 및 관련 방법
|
|
TN2016000553A1
(en)
|
2014-06-13 |
2018-04-04 |
Acceleron Pharma Inc |
Methods and compositions for treating ulcers
|
|
WO2016183280A1
(en)
|
2015-05-13 |
2016-11-17 |
Celgene Corporation |
Treatment of beta-thalassemia using actrii ligand traps
|